The objective of the current study is to investigate the safety, efficacy, and feasibility of multiple doses of intranasal (IN) ketamine for suicidal ideation Veterans.
To address the significant need for effective treatment of suicidal ideation in Veterans, this trial is designed as an open label pilot study of intranasal ketamine in 15 people.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
8 doses of intranasal ketamine; 40 mg per dose.
James J. Peters VA Medical Center
The Bronx, New York, United States
Change in Beck Scale for Suicidal Ideation (BSSI)
Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.
Time frame: Baseline Visit to End of Treatment Visit- approximately 3-4.5 weeks
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
Time frame: Baseline Visit to End of Treatment Visit- approximately 3-4.5 weeks
The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR)
QIDS-SR is a 16-item self-rated instrument designed to assess the severity of depressive symptoms present in the past seven days (Rush et al. 2003). The 16 items cover the nine symptom domains of major depression, and are rated on a scale of 0-3.
Time frame: Baseline Visit to End of Treatment Visit- approximately 3-4.5 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.